Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 28 May 2021 consists of 979,749,321 ordinary shares of 1 pence each, none of which are held in treasury.
May 28, 2021
· 1 min read